FLUVANTAGE Trademark

Trademark Overview

On Friday, October 19, 2012, a trademark application was filed for FLUVANTAGE with the United States Patent and Trademark Office. The USPTO has given the FLUVANTAGE trademark a serial number of 79121053. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Wednesday, October 19, 2022. This trademark is owned by NOVARTIS AG. The FLUVANTAGE trademark is filed in the Pharmaceutical Products category with the following description:

Vaccines for human use
fluvantage

General Information

Serial Number79121053
Word MarkFLUVANTAGE
Filing DateFriday, October 19, 2012
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateWednesday, October 19, 2022
Registration Number4319465
Registration DateTuesday, April 16, 2013
Mark Drawing5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, January 29, 2013

Trademark Statements

Goods and ServicesVaccines for human use
Pseudo MarkFLU VANTAGE
Indication of Colors claimedColor is not claimed as a feature of the mark.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, November 22, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSeqirus UK Limited
Party Type31 - New Owner After Registration
Legal Entity Type98 - Unknown
AddressGB
Party NameNOVARTIS AG
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressCH
Party NameNOVARTIS AG
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressCH
Party NameNOVARTIS AG
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCH

Trademark Events

Event DateEvent Description
Monday, May 15, 2023NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Monday, May 15, 2023DEATH OF INTERNATIONAL REGISTRATION
Saturday, October 3, 2020TOTAL INVALIDATION PROCESSED BY THE IB
Sunday, September 6, 2020TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Saturday, August 29, 2020INVALIDATION PROCESSED
Wednesday, July 22, 2020TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, November 22, 2019CANCELLED SECTION 71
Thursday, June 6, 2019NEW REPRESENTATIVE AT IB RECEIVED
Monday, April 16, 2018COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Tuesday, May 23, 2017REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED
Tuesday, January 31, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, November 3, 2016CHANGE OF NAME/ADDRESS REC'D FROM IB
Thursday, September 29, 2016ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, September 29, 2016TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sunday, November 15, 2015CHANGE OF OWNER RECEIVED FROM IB
Saturday, July 13, 2013NOTIFICATION PROCESSED BY IB
Thursday, May 16, 2013FINAL DISPOSITION NOTICE SENT TO IB
Thursday, May 16, 2013FINAL DISPOSITION PROCESSED
Thursday, May 16, 2013GRANT OF PROTECTION CREATED, TO BE SENT TO IB
Sunday, April 28, 2013NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, April 16, 2013REGISTERED-PRINCIPAL REGISTER
Sunday, March 10, 2013NOTIFICATION PROCESSED BY IB
Tuesday, January 29, 2013PUBLISHED FOR OPPOSITION
Wednesday, January 23, 2013NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, January 23, 2013NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, January 9, 2013NOTICE OF PUBLICATION
Friday, December 21, 2012APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, December 21, 2012ASSIGNED TO EXAMINER
Saturday, December 15, 2012APPLICATION FILING RECEIPT MAILED
Tuesday, December 11, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, December 7, 2012SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

fluvantage human vaccines